Patient Access Network Foundation uses the following criteria to
determine eligibility for assistance:
1. You have to be insured and your insurance has to cover the
medication for which you are seeking assistance.
2. The medication you take must fight the disease directly.
3. You have to be a US resident.
4. Your income must fall below 400% of the Federal Poverty
Level.
Click
here
for the Federal Poverty Guidelines
applications for new and renewal patients
are being accepted and approved; however grants are not
allocated until funds are made available.
Cutaneous T-cell lymphoma (CTCL) is a general term for many
lymphomas of the skin and can include mycosis fungoides (the most
common type of CTCL),Sézary syndrome,lymphomatoid papulosis,
cutaneous anaplastic large cell lymphoma, adult T-cell
leukemia/lymphoma, peripheral T-cell lymphoma, lymphomatoid
granulomatosis, granulomatous slack skin disease, and pagetoid
reticulosis to name a few. Generally, CTCL is a low-grade lymphoma
which primarily affects the skin. Over time, in about 10% of the
cases, CTCL can progress to the lymph nodes and internal organs. In
severe cases, the malignant mature T-cells circulate in the blood
stream in addition to appearing on the skin's surface.
The primary payer for CTCL patients is Medicare, followed by
private payers; however, both can lead to access issues for many
patients. Medicare lacks a cap on coinsurance in select sites of
service, and private coverage can vary dramatically, leaving many
patients with extremely high co-payments and out-of-pocket maximums.
As a result, low to moderate income beneficiaries are often unable
to afford the out-of-pocket costs associated with their prescribed
therapies. The Patient Access Network Foundation may be able to
provide these patients assistance with their cost sharing
requirements.
